Pharmacokinetics of troglitazone in patients with renal insufficiency

Clinical Drug Investigation

Volumn 17, Issue 2, 1999, Pages 127-136

  Knowlton, Philip W ^a   Loi, Cho Ming ^a   Vassos, Artemios B ^a   Blum, Robert A ^b   Brodfuehrer, Joanne I ^a   Randinitis, Edward J ^a   Sedman, Allen J ^a   Koup, Jeffrey R ^a  

^a PFIZER INC   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; TROGLITAZONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; ULTRACENTRIFUGATION; VOMITING;

EID: 0033013831     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917020-00007     Document Type: Article

References (22)

1. 1. Horikoshi H, Yoshioka T, Kawasaki T, et al. Troglitazone (CS-045), a new antidiabetic drug. Annual Report, Sankyo Research Laboratories 1994; 46: 1-57
2. 2. Lebovitz HE, Feinglos MN. Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1987; 1: 189-98
3. 3. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9
4. 4. Ciaraldi TP, Gilmore A, Olefsky JM, et al. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990; 39: 1056-62
5. 5. Fujiwara T, Yoshioka S, Yoshioka T, et al. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-58
6. 6. Iwamoto Y, Kuzuya T, Matsuda A, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991; 14: 1083-6
7. 7. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203
8. 8. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-93
9. 9. Loi C-M, Randinitis EJ, Vassos AB, et al. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 1997; 37: 1114-20
10. 10. Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency. Eur J Pharmacol 1998; 54: 567-71
11. 11. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338 (13): 916-7
12. 12. DeFronzo RA. Diabetic nephropathy. In: Porte Jr D and Sherwin RS, editors. Ellenberg & Rifkin's Diabetes Mellitus. 5th ed. Stamford: Appleton & Lange, 1997: 971-1008
13. 13. Izumi T, Enomoto S, Hosiyama K, et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 1996; 277: 1630-41
14. 14. Karara AH, Frye RF, Hayes PE, et al. Pharmacokinetics of abecarnil in patients with renal insufficiency. Clin Pharmacol Ther 1996; 59: 520-8
15. 15. Rogers HJ, Savitsky JP, Glenn B, et al. Kinetics of single doses of fenbufen in patients with renal insufficiency. Clin Pharmacol Ther 1981; 29: 74-80
16. 16. Koup JR. Disease states and pharmacokinetics. J Clin Pharmacol 1989; 29: 674-9
17. 17. Tozer TN. Implication of altered plasma protein binding in disease states. In: Benet LZ, editor. Pharmacokinetic basis for drug treatment. New York: Raven Press, 1984: 173
18. 18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31
19. 19. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekkar Inc., 1982
20. 20. Loi C-M, Alvey CW, Randinitis EJ, et al. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 1997; 37 (11): 1038-47
21. 21. Young MA, Eckland DJA, Eastmond R, et al. Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients. Ann Med 1998; 30: 206-12
22. 22. Rezulin product labeling. Physicians Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Company, 1998: 2118-21